GlassScriptPhysician profile
Fahad Khan
NPI 1073742029
$944.77
in general payments reported to CMS, 2019-2025
12 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $23.77 · 2021: $33.88 · 2022: $29.99 · 2023: $255 · 2024: $325 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646 · Education: $43.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.96 |
| Education | $43.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $414.55 | 2022-2024 | Benlysta |
| Boston Scientific Corporation | $181.87 | 2019-2024 | Varithena Administration Pack |
| Astrazeneca Pharmaceuticals LP | $65.41 | 2024-2025 | Saphnelo |
| Travere Therapeutics, INC. | $62.30 | 2023-2025 | Filspari |
| Alexion Pharmaceuticals, INC. | $58.27 | 2024-2025 | Ultomiris, Strensiq |
| Novartis Pharmaceuticals Corporation | $42.06 | 2025 | |
| Allergan, INC. | $23.77 | 2020 | |
| Portola Pharmaceuticals, LLC | $22.98 | 2019 | |
| Octapharma USA, INC. | $22.82 | 2024 | Octagam Immune Globulin (Human) |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.86 | 2023 | Gvoke Hypopen |
| Medtronic, INC. | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.